BR112023024701A2 - Métodos de tratamento de doenças do fígado - Google Patents

Métodos de tratamento de doenças do fígado

Info

Publication number
BR112023024701A2
BR112023024701A2 BR112023024701A BR112023024701A BR112023024701A2 BR 112023024701 A2 BR112023024701 A2 BR 112023024701A2 BR 112023024701 A BR112023024701 A BR 112023024701A BR 112023024701 A BR112023024701 A BR 112023024701A BR 112023024701 A2 BR112023024701 A2 BR 112023024701A2
Authority
BR
Brazil
Prior art keywords
methods
patients
nash
liver
treatment
Prior art date
Application number
BR112023024701A
Other languages
English (en)
Portuguese (pt)
Inventor
Kaneta Noboru
Oshima Ryu
Shona Sanchita Pendse
Tanigawa Ryohei
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of BR112023024701A2 publication Critical patent/BR112023024701A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112023024701A 2021-05-27 2022-05-25 Métodos de tratamento de doenças do fígado BR112023024701A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163194088P 2021-05-27 2021-05-27
PCT/IB2022/054867 WO2022249071A1 (en) 2021-05-27 2022-05-25 Pemafibrate and/or tofogliflozin for use in treating liver disease

Publications (1)

Publication Number Publication Date
BR112023024701A2 true BR112023024701A2 (pt) 2024-02-15

Family

ID=82020168

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023024701A BR112023024701A2 (pt) 2021-05-27 2022-05-25 Métodos de tratamento de doenças do fígado

Country Status (10)

Country Link
US (1) US20240277745A1 (cg-RX-API-DMAC10.html)
EP (1) EP4346809B1 (cg-RX-API-DMAC10.html)
JP (1) JP2024520020A (cg-RX-API-DMAC10.html)
KR (1) KR20240013203A (cg-RX-API-DMAC10.html)
CN (1) CN117677385A (cg-RX-API-DMAC10.html)
AU (1) AU2022282651A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023024701A2 (cg-RX-API-DMAC10.html)
CA (1) CA3221073A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023013886A (cg-RX-API-DMAC10.html)
WO (1) WO2022249071A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2024014524A1 (cg-RX-API-DMAC10.html) * 2022-07-15 2024-01-18
CN115991682A (zh) * 2023-03-21 2023-04-21 广州佳途科技股份有限公司 一种培马贝特-d4的制备方法及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI696462B (zh) * 2013-07-10 2020-06-21 日商興和股份有限公司 非酒精性脂肪性肝疾病治療劑
EP3569250B1 (en) * 2017-01-11 2025-04-30 Kowa Company, Ltd. Pemafibrate in combination with a sglt2 inhibitor for the prophylactic or therapeutic treatment of liver diseases nonalcoholic fatty liver disease

Also Published As

Publication number Publication date
CN117677385A (zh) 2024-03-08
AU2022282651A1 (en) 2023-12-07
KR20240013203A (ko) 2024-01-30
EP4346809A1 (en) 2024-04-10
CA3221073A1 (en) 2022-12-01
MX2023013886A (es) 2024-04-19
JP2024520020A (ja) 2024-05-21
WO2022249071A1 (en) 2022-12-01
EP4346809B1 (en) 2026-07-15
US20240277745A1 (en) 2024-08-22

Similar Documents

Publication Publication Date Title
BR112022020817A2 (pt) Inibidores de kif18a para tratamento de doenças neoplásicas
Koeppen et al. Medicinal leech therapy in pain syndromes: a narrative review
Nitecka-Buchta et al. Myorelaxant effect of bee venom topical skin application in patients with RDC/TMD Ia and RDC/TMD Ib: a randomized, double blinded study
EA201691847A1 (ru) Способы снижения сердечно-сосудистого риска
Joo et al. The clinical utility of extracorporeal shock wave therapy for burn pruritus: A prospective, randomized, single-blind study
Tsai et al. Low-level laser irradiation stimulates tenocyte migration with up-regulation of dynamin II expression
PH12020551427A1 (en) Epinephrine spray formulations
EA202092154A1 (ru) Комбинированная терапия
EA200971053A1 (ru) Способы лечения кожных язв
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
BRPI0409919A (pt) combinações para o tratamento de doenças envolvendo proliferação, migração ou apoptose celular de células de células de mieloma, ou angiogênese
BR112023002453A2 (pt) Composições de agente de via de estresse de replicação e métodos para tratar câncer
MX2025003477A (es) Uso de reboxetina para el tratamiento de narcolepsia
Doley et al. Effect of positional release therapy and deep transverse friction massage on gluteus medius trigger point-a comparative study
ATE525084T1 (de) Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus
CO2022010592A2 (es) Métodos de tratamiento de la esplenomegalia
BR112022019649A2 (pt) Interação das proteínas sars-cov-2 com mecanismos moleculares e celulares de células hospedeiras e formulações para tratar o covid-19
BR112022008580A2 (pt) Métodos para tratar transtornos depressivos
Lauria et al. Effects of photobiomodulation therapy on the local experimental envenoming by Bothrops leucurus snake
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
MX2023013886A (es) Pemafibrato y/o tofogliflozin para uso en el tratamiento de enfermedad del higado.
Chandra et al. Progresses in wound healing: integrating nutrition, physical therapy, traditional and alternative medicine, and novel technologies
BR112022010733A2 (pt) Métodos para tratar dor
BR112022003639A2 (pt) Agente bioestimulante para tratamento de plantas e/ou de sementes de plantas
BR112022001814A2 (pt) Métodos de tratamento de câncer multifocal